- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05300932
A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis
Efficacy and Safety of Baricitinib in Systemic Sclerosis: a Phase IV, Double-blinded, Controlled Study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a 48 weeks, prospective, double-blind, controlled study. The specific objectives of this study are to:
- Determine whether Baricitinib is effective and safe in the treatment of patients with diffuse cutaneous (dc)SSc when compared to patients treated with CTX. In this study, stand of care of GC is permitted to use.
- Determine whether Baricitinib is more effective than CTX, as measured by change in CRISS, which is a composite outcome measure provisionally endorsed by the ACR for scleroderma clinical trials. It incorporates change in the mRSS, FVC percent predicted, physician and patient global assessments, and HAQ-DI. Additionally, hemoglobin corrected diffusion capacity (DLCO), Medsger Severity Scale (MSS), and by other physician and patient derived outcome measures will be used.
- Determine the biological activity of Baricitinib vs CTX as assessed by effect on histology of skin, gene expression of skin and blood, change in B-Cell profiles including assessment of B regulatory cells, and effect on serological and cutaneous biomarkers of disease activity.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: YIKAI YU
- Phone Number: 14849955917
- Email: yuyikai@163.com
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Recruiting
- Tongji Hospital
-
Contact:
- AIHUA DU, M.D
- Phone Number: +86 2783662886
-
Principal Investigator:
- YIKAI YU, M.D
-
Sub-Investigator:
- SHAOXIAN HU, M.D
-
Sub-Investigator:
- WEI TU, M.D
-
Sub-Investigator:
- RUI XING, M.D
-
Sub-Investigator:
- CONG YE, M.D
-
Sub-Investigator:
- FEI YU, M.D
-
Sub-Investigator:
- GUIFEN SHEN, M.D
-
Sub-Investigator:
- JIJUN YANG, M.D
-
Sub-Investigator:
- MEI YU, M.D
-
Sub-Investigator:
- XIAOFANG LUO, M.D
-
Wuhan, Hubei, China, 430030
- Recruiting
- Department of RheumatologyTongji Hospital
-
Contact:
- YIKAI YU, M.D
- Phone Number: 13476069099
- Email: yuyikai@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of Systematic Sclerosis (SSc), as defined using the 2013 American College of Rheumatology/ European Union League Against Rheumatism classification of SSc
- Diffuse Systemic Sclerosis (dcSSc) as defined by LeRoy and Medsger
- Disease duration of ≤ 36 months (defined as time from the first non-Raynaud phenomenon manifestation)
- For disease duration of ≤ 18 months: ≥ 10 and ≤ 35 mRSS units at the screening visit
- For disease duration of >18-36 months: ≥ 15 and ≤ 45 mRSS units at the screening visit and one of the following:
1)Increase ≥ 3 in mRSS units compared with the last visit within previous 1-6 months 2)Involvement of one new body area with ≥ 2 mRSS units compared with the last visit within the previous 1-6 months 3)Involvement of two new body areas with ≥ 1 mRSS units compared with the last visit within the previous 1-6 months 4)Presence of 1 or more Tendon Friction Rub 6.Age ≥ 18 years at the screening visit 7.If female of childbearing potential, the patient must have a negative pregnancy test at screening and baseline visits 8.Oral corticosteroids (≤ 10 mg/day of prednisone or equivalent) and NSAIDs are permitted if the patient is on a stable dose regimen for 2 weeks prior to and including the baseline visit.
9.ACE inhibitors, calcium-channel blockers, proton-pump inhibitors, and/or oral vasodilators are permitted if the patient is on a stable dose for ≥ 2 weeks prior to and including the baseline visit.
Exclusion Criteria:
- Rheumatic disease other than dcSSc; it is acceptable to include patients with fibromyalgia and scleroderma-associated myopathy
- Limited cutaneous systemic sclerosis or sine scleroderma at the screening visit
- Major surgery (including joint surgery) within 8 weeks prior to screening visit
- Infected ulcer prior to treatment
- Treatment with any investigational agent within ≤ 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) of the baseline visit
- Previous treatment with cell-depleting therapies, including investigational agents, including but not limited to, CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19, and ABA
- Anti-CD20 within 12 months prior to baseline visit.
- Use of Intravenous Immunoglobulin (IVIG) within 12 weeks prior to baseline visit
- Previous treatment with chlorambucil, bone marrow transplantation, or total lymphoid irradiation
- Immunization with a live/attenuated vaccine within ≤ 4 weeks prior to the baseline visit
- Treatment with methotrexate, hydroxychloroquine, cyclosporine A, azathioprine, mycophenolate mofetil rapamycin, colchicine, or D-penicillamine, within≤ 4 weeks prior to the baseline visit
- Treatment with etanercept within ≤ 2 weeks, infliximab, certolizumab, golimumab, ABA or adalimumab within ≤ 8 weeks, anakinra within ≤ 1 week prior to the baseline visit
- Pulmonary disease with FVC ≤ 50% of predicted, or DLCO (uncorrected for hemoglobin ) ≤ 40% of predicted at the screening visit
- Pulmonary arterial hypertension (PAH) as determined by right heart catheterization or on PAH approved medications for PAH. It is acceptable to use PDFE-5 inhibitors for Raynaud's and digital ulcers.
- Subjects at risk for tuberculosis (TB). Specifically excluded from this study will be participants with a history of active TB within the last 3 years, even if it was treated; a history of active TB greater than 3 years ago, unless there is documentation that the prior anti-TB treatment was appropriate in duration and type; current clinical, radiographic, or laboratory evidence of active TB; and latent TB that was not successfully treated (≥ 4 weeks).
- Positive for hepatitis B surface antigen prior to the baseline visit
- Positive for hepatitis C antigen, if the presence of hepatitis C virus was also shown with polymerase chain reaction or recombinant immunoblot assay prior to baseline visit
- Subjects at risk for tuberculosis (TB). Specifically excluded from this study will be participants with a history of active TB within the last 3 years, even if it was treated; a history of active TB greater than 3 years ago, unless there is documentation that the prior anti-TB treatment was appropriate in duration and type; current clinical, radiographic, or laboratory evidence of active TB; and latent TB that was not successfully treated (≥ 4 weeks).
- Any of the following at the screening visit: Hemoglobin <8 g/dL; ANC < 1,000/mm3 (<1 x 109/L); platelets < 100,000/mm3 (<100 x 109/L); serum creatinine > 2 x ULN; serum ALT or AST > 2 x ULN
- Severe skin thickening (mRSS 3) on the inner aspects of thighs, upper arms, or abdomen
- Patients with a history of anaphylaxis to Baricitinib or cyclophosphamide
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Baricitinib 4mg
4mg of oral Baricitinib everyday for 48 weeks.
|
Orally take Baricitinib 4mg everyday for 48 weeks
Other Names:
|
Active Comparator: Cyclophosphamide
Subject received cyclophosphamide 400mg intravenous drip every 2 weeks combined with oral Prednisone 10-15 mg/d (standard of care)through the 24 weeks double blind period.
Subsequently, subject were administered oral Baricitinib 4mg everyday through the 24-48 weeks open label period.
|
Subject received cyclophosphamide 400mg intravenous drip every 2 weeks combined with oral Prednisone 10-15 mg/d (standard of care)through the 24 weeks double blind period.
Subsequently, subject were administered oral Baricitinib 4mg everyday through the 24-48 weeks open label period.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in modified Rodnan skin score (mRSS) at week 24
Time Frame: 24 weeks
|
Change in modified Rodnan skin score (mRSS) at week 24 performed by the same investigator at week 0 and week 24 and the change in mRSS will be calculated following the formula: ΔmRSS= mRSSw24 - mRSSw0. To measure mRSS, skin thickness of the patient is rated by palpation at each of 17 anatomic sites using a scale of 0-3 (0 = normal skin; 1= mild thickness; 2= moderate thickness; 3=severe thickness with an inability to pinch the skin into a fold). The scores at each site are summed with a minimum of 0 and a maximum of 51 (17 sites) |
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of death
Time Frame: 24 & 48 weeks
|
Incidence of death
|
24 & 48 weeks
|
Incidence of Adverse Events
Time Frame: 24 & 48 weeks
|
according to the Common Terminology Criteria for Adverse Events (CTCAE) toxicity grading scale
|
24 & 48 weeks
|
Incidence of Severe Adverse Events
Time Frame: 24 & 48 weeks
|
according to the Common Terminology Criteria for Adverse Events (CTCAE) toxicity grading scale
|
24 & 48 weeks
|
Change in modified Rodnan skin score at 12,24,32,40,48 weeks
Time Frame: 12,24,32,40,48 weeks
|
Change in modified Rodnan skin score at 12,24,32,40,48 weeks
|
12,24,32,40,48 weeks
|
Proportion of patients who improved mRSS at 12,24,32,40,48 weeks
Time Frame: 12,24,32,40,48 weeks
|
Proportion of patients who improved mRSS at 12,24,32,40,48 weeks
|
12,24,32,40,48 weeks
|
Proportion of patients with an active disease according to the European scleroderma trials and research group (EUSTAR)SSc activity score at 12,24,48 weeks
Time Frame: 12,24,32,40,48 weeks
|
EUSTAR SSc activity index score from 0 to 10 - a cut-off ≥ 2.5 identifies patients with active disease
|
12,24,32,40,48 weeks
|
Change in the Combined Response Index in Diffuse Systemic Sclerosis (CRISS) score
Time Frame: 24,48 weeks
|
composite response index
|
24,48 weeks
|
SSc disease activity
Time Frame: 12,24,32,40,48 weeks
|
Physicians visual analogue scale range from 0 (min) to 10 (max) - 0=no activity, 10=maximum activity Patients visual analogue scale range from 0 (min) to 10 (max) - 0=no activity, 10=maximum activity
|
12,24,32,40,48 weeks
|
Short Form-36 (SF-36) health questionnaire
Time Frame: 0, 12,24,32,40,48 weeks
|
self-administered questionnaire of 36 items assessing the following 8 domains : physical functioning, bodily pain, role limitations attributable to physical health problems, general health perceptions, mental health, role limitations to emotional problems, vitality and social functioning (scale from 0 to 100)
|
0, 12,24,32,40,48 weeks
|
EurolQol-5Domain (EQ-5D) health questionnaire
Time Frame: 0, 12,24,32,40,48 weeks
|
self reported measure of quality of life - (scale from 0 to 100)
|
0, 12,24,32,40,48 weeks
|
Health Assessment Questionnaire Disability Index (HAQ-DI) scale
Time Frame: 0, 12,24,32,40,48 weeks
|
self administered 20 questions- score range from 0 (no disability) to 3 (severe disability)
|
0, 12,24,32,40,48 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: AIHUA DU, Tongji Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Skin Diseases
- Connective Tissue Diseases
- Sclerosis
- Scleroderma, Systemic
- Scleroderma, Diffuse
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
Other Study ID Numbers
- TJ-SSc202203
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Sclerosis
-
Horizon Pharma Ireland, Ltd., Dublin IrelandEnrolling by invitationDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicKorea, Republic of, France, United States, Spain, Mexico, Japan, Argentina, Greece, Israel
-
Michael M. PhamTerminatedSystemic Sclerosis | Scleroderma, Systemic | Scleroderma, Diffuse | Diffuse Cutaneous Systemic Sclerosis | Interstitial Lung Disease | Scleroderma | Systemic Sclerosis, Diffuse | Diffuse Systemic Sclerosis | Pulmonary Fibrosis Interstitial | Diffuse Scleroderma | Diffuse Cutaneous Scleroderma | Progressive Systemic... and other conditionsUnited States
-
Horizon Therapeutics Ireland DACRecruitingDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicNetherlands, Spain, Germany, United States, Japan, France, Italy, Korea, Republic of, Portugal, Israel, Greece, Argentina, Austria, Mexico, Poland, Switzerland, United Kingdom, Romania, Chile
-
University of ManchesterCompletedEarly Diffuse Cutaneous Systemic Sclerosis
-
Fred Hutchinson Cancer CenterNational Institute of Allergy and Infectious Diseases (NIAID)CompletedSystemic Scleroderma | Severe Systemic SclerosisUnited States
-
Kadmon, a Sanofi CompanyTerminatedDiffuse Cutaneous Systemic Sclerosis | System; SclerosisUnited States
-
Boston UniversityCompleted
-
Federal University of São PauloUnknown
-
University Hospital, Strasbourg, FranceRecruitingJuvenile Systemic SclerosisFrance
Clinical Trials on Baricitinib
-
Assistance Publique - Hôpitaux de ParisTerminated
-
Aaron R. MangoldCompletedCutaneous Lichen PlanusUnited States
-
Tianjin Medical University General HospitalRecruitingNMO Spectrum DisorderChina
-
Peking University People's HospitalRecruitingImmune Thrombocytopenia | ITPChina
-
Eli Lilly and CompanyCompletedHealthy VolunteersUnited Kingdom
-
University of WashingtonWithdrawn
-
University of ManchesterKarolinska Institutet; Eli Lilly and Company; Clinical Trials Unit, ManchesterCompletedIdiopathic Inflammatory MyopathiesUnited Kingdom
-
Eli Lilly and CompanyRecruitingCovid19 | Corona Virus InfectionUnited States, Spain, Mexico, Belgium, Brazil
-
Eli Lilly and CompanyRecruitingJuvenile Idiopathic ArthritisBelgium, Spain, Australia, India, Japan, Italy, Czechia, Germany, Austria, France, United Kingdom, China, Mexico, Israel, Brazil, Denmark, Poland, Russian Federation, Argentina, Turkey